Renal stone, bleeding, percutaneous nephrolithotomy. Calculus of kidney
Conditions
Interventions
Intervention 1: Intervention group: tranexamic acid (TRANEXIP, Caspian Tamin Pharmaceutical Company, Iran) which is an antifibrinolytic drug and inhibits plasminogen activation
10 mL of 100 mg/mL injectable solution per dose administered intravenously and repeated at 8 hourly intervals to reach maximum dose of 6 gr. Intervention 2: Control group: placebo.
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients older than 18 years of age with renal stone Serum creatinin level of 1.5 mg/dL or less
Exclusion criteria
Exclusion criteria: history of allergy to tranexamic acid Ongoing arterial or venous thrombosis Creatinine level of more than 1.5 mg/dL Acquired defective color vision Subarachnoid hemorrhage Concurrent use of oral contraceptives
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemoglobin drop. Timepoint: Prior to surgery, 4 hours after surgery, post-op days one and two. Method of measurement: Blood sample examination.;Number of transfusions. Timepoint: Postoperative days. Method of measurement: Checklist.;Postoperative length of stay. Timepoint: Postoperative days. Method of measurement: Checklist.;Drug adverse effect. Timepoint: Postoperative days. Method of measurement: Checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarshad Gholipour
Esfahan University of Medical Sciences
Outcome results
None listed